Menopause & Post-Menopause Longevity Protocol: Transdermal Estradiol, Micronized Progesterone, Testosterone Dosing, DEXA/ApoB Diagnostics & Annual Costs

01Why 12-minute visits fail women after menopause

Menopause is confirmed after 12 months without a period, and it marks the start of a phase that can last 30 years or more. In a short insurance visit, it often gets one of two responses: a quick “hormones cause cancer” warning that dates back to the 2002 Women’s Health Initiative headlines, or a refill with no plan for heart, bone or brain health.

The specific gaps:

• Under-treatment. After 2002, hormone therapy use fell sharply, even for younger women who later analyses showed were at low risk. Many women still suffer moderate to severe hot flashes and broken sleep for years.
• No cardiovascular reset. LDL cholesterol and ApoB rise after menopause, and heart disease is the leading cause of death in women. A standard lipid panel every few years rarely includes ApoB or a one-time Lp(a).
• Bone loss is found late. Bone density drops fastest in the first years after menopause, but routine screening usually starts at 65 unless risk factors are noticed.
• Vaginal and bladder symptoms go unmentioned. Genitourinary syndrome of menopause affects about half of women and worsens without treatment; low-dose vaginal estrogen is safe for most women.
• Muscle loss is ignored. Strength and muscle mass decline faster after menopause, which affects balance, blood sugar and fracture risk, yet few visits include a word about resistance training or protein.

A longer visit lets a clinician weigh your personal risks, choose the safest route, plan screening and revisit the decision yearly. If you are comparing clinics or telehealth services for this, see Winona vs. Evernow vs. Alloy and Midi vs. Tia vs. Parsley.

02Who is a candidate: timing, route and real risks

The Menopause Society’s 2022 position statement, which ACOG and the Endocrine Society broadly share, makes four points worth knowing.

• Timing matters. For women under 60 or within 10 years of menopause without contraindications, benefits generally outweigh risks for hot flashes and preventing bone loss. Starting later carries higher absolute risks of heart disease, stroke, clots and dementia, so it needs a more careful, individual decision.
• Route matters. Transdermal estradiol, through the skin, avoids first-pass liver metabolism; observational studies link it to lower clot and stroke risk than oral estrogen.
• Progestogen type may matter. If you have a uterus you need a progestogen to prevent endometrial cancer. Oral micronized progesterone may carry less breast cancer risk than synthetic progestins, but this comes from observational data and evidence is limited.
• Hormone therapy is not for prevention alone. It is not recommended solely to prevent heart disease or dementia.

On breast cancer: in the WHI, combined estrogen plus a synthetic progestin was linked to a small increase in risk with longer use, while estrogen alone in women without a uterus was not. In November 2025 the FDA announced it would remove most boxed-warning language from menopausal hormone therapy labels; the labels still describe risks, and your personal history still decides.

03The menopause longevity panel, with billing codes

You do not need hormone levels to start therapy if you are over 45 and have gone 12 months without a period. The panel below is about long-term risk. Ranges vary by lab; read your own report. Targets marked as practitioner targets go beyond guidelines where evidence is limited.

Table 1 · Codes as commonly used; payers differ. Use N95.1 when treating symptoms and Z79.890 for monitoring long-term hormone therapy.

Postmenopausal bleeding (N95.0) always needs evaluation, usually a transvaginal ultrasound (76830) and often an endometrial biopsy (58100).

04Dosing: estradiol, progesterone and testosterone

These are typical starting points that your clinician adjusts to your symptoms. All of the first-line options below are FDA-approved and bioidentical.

Transdermal estradiol

Patch 0.025–0.05 mg/day to start, changed once or twice weekly; usual range up to 0.1 mg/day. Gels and sprays are alternatives. Oral estradiol 0.5–1 mg is cheaper but carries more clot risk in observational data.

Oral micronized progesterone

If you have a uterus: 100 mg nightly every day, or 200 mg nightly for 12 days each month. Take at bedtime because it causes drowsiness. Generic and brand versions contain peanut oil. A combined estradiol/progesterone capsule (Bijuva) is also FDA-approved.

No uterus

Estrogen alone; no progestogen needed.

Low-dose vaginal estrogen

For dryness, pain with sex or recurrent UTIs, alone or alongside systemic therapy; minimal absorption. See the GSM playbook.

Testosterone: one indication, careful dosing

The 2019 Global Consensus Position Statement, endorsed by The Menopause Society and the Endocrine Society, supports testosterone for one use: low sexual desire that causes distress (hypoactive sexual desire disorder) after menopause. Evidence does not support it for energy, mood, bone or cognition. There is no FDA-approved testosterone product for women in the US, so clinicians use about one-tenth of a male transdermal dose off-label, or a compounded cream. Testosterone is a Schedule III controlled substance. Check levels at baseline, 3–6 weeks and every 6 months, keep them in the premenopausal range, and stop if there is no benefit by 6 months.

If hormones are not an option: fezolinetant (Veozah), elinzanetant (Lynkuet) and paroxetine 7.5 mg are FDA-approved for hot flashes; venlafaxine, gabapentin and oxybutynin are used off-label. For osteoporosis, bisphosphonates or other bone drugs may be needed in addition to, or instead of, estrogen.

05Muscle, bone and heart: the lifestyle and supplement layer

Hormone therapy treats symptoms and slows bone loss, but most of the longevity benefit after menopause comes from what you do every week. These have the strongest evidence.

Table 2 · Evidence summarized from The Menopause Society, Bone Health & Osteoporosis Foundation guidance and published trials.

In a trial of postmenopausal women with low bone mass (LIFTMOR), supervised high-intensity resistance and impact training improved bone density safely. If you have osteoporosis, start with a trained coach or physical therapist. Sleep matters as well: treating night sweats, screening for sleep apnea (more common after menopause) and keeping a regular sleep schedule support blood pressure, blood sugar and mood. Bundled “hormone support” supplements sold with pellet programs, often $80–$180 a month, have little evidence; the BioTE pricing audit lists questions to ask before you sign up.

06Realistic 12-month budget: cash-pay vs. insurance-hybrid

Both columns use FDA-approved estradiol and progesterone. Optional lines are included as ranges starting at $0.

Table 3 · IntegrativeGyn.com estimates from 2026 clinic, imaging and pharmacy pricing. Prices change; confirm with each provider.

The pellet line adds up three or four insertions a year ($2,100–$4,200 at typical fees), $0–$800 in booster and lab-check fees, and $960–$2,160 in bundled supplements. A compounded estradiol/progesterone cream at $65–$145 a month costs $780–$1,740 a year, usually more than an insured patch and without FDA approval. To model your own numbers over three years, use the BHRT cost comparator.

What pushes you toward the low or high end

• Low end: generic estradiol patch and progesterone on your pharmacy benefit, labs and screening through insurance, two follow-ups, and only vitamin D as a supplement.
• High end: cash visits and labs, a brand-name gel or spray, off-label testosterone, vaginal estrogen paid in cash, a calcium score and a broader supplement plan.
• Year two and beyond: once your dose is stable, most women need one or two visits and one set of labs a year, so ongoing costs usually fall by a third or more.

Cost per year matters less than cost over the 5–10 years many women stay on therapy. That is where the gap between an insured patch and a pellet program grows into five figures.

07How to pay less and what to do next

Generic estradiol patches and micronized progesterone are on most insurance formularies, often at $15–$45 a month. Without coverage, discount-card prices are usually lower than compounded alternatives. If you pay a cash-pay clinician, ask for a superbill: 99205 for the intake (commercial allowable roughly $260–$485) and 99215 for follow-ups ($195–$365) with N95.1. Screening mammograms, and DEXA scans for women who qualify, are preventive services that most plans cover in-network.

1. Month 1 — Intake: history, blood pressure, breast and clot risk review; order the longevity panel through insurance.
2. Months 1–3 — Start transdermal estradiol and progesterone, or a non-hormonal option; begin strength training.
3. Month 3 — Follow-up: adjust the dose to symptoms; report any bleeding after the first 6 months.
4. Month 6 — Consider testosterone only if distressing low desire persists; add vaginal estrogen if needed.
5. Month 12 — Annual review: lipids, ApoB, HbA1c, mammogram, DEXA timing, and whether to continue, adjust or taper.

Pay with HSA or FSA funds where you can; the superbill and HSA/FSA guide explains Letters of Medical Necessity. If your menopause came early or surgically, read the surgical menopause and POI protocol, because the dosing goals differ.

Ask for this in writing

Please confirm whether the hormones you prescribe are FDA-approved or compounded, the monthly cost at my pharmacy, any program or membership fees, how often labs are required and what they cost, and whether you provide an itemized superbill with CPT and ICD-10 codes.

This page is educational and is not individual medical advice; discuss any test or treatment with your own clinician.